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ABSTRACT 
 
Primary tubal carcinoma is a rare carcinoma type 
that is quite difficult to diagnose preoperatively. In 
this case report, a patient who was operated by 
reason of preliminary diagnosis of tuboovarian 
abscess in our clinic was diagnosed with primary 
tubal adenocarcinoma histopathologically. The 
patient was designated as stage Iic, and she 
received chemotherapy and radiotherapy. She 
developed recurrence after a remission period, 
and her illness  aggrevated into stage IV. After 36 
months from diagnosis, the patient died due to 
respiratory failure. 
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Primary tubal carcinomas represent 0.15 
%-1.8% of all female genital system 
carcinomas and are extremely rare,1 with 
an incidence of 3.61,000,000.2 It was first 
reported in 1847, and 1600 cases have 
been reported through 2000 with 20-30 
new cases reported annually.3 The 
average age at diagnosis is between 55-
60 years old with 6% of cases  younger 
than 40 years old.4 Clinical presentation, 
staging and treatment approaches are 
identical to those used for ovarian 
carcinomas. Indeed, both carcinomas 
have some common features: similar age 
spectrum, frequent occurence in 
nulliparous females, predominantly 
serous papillary histology, correlation 
between stage and prognosis, correlation 
between residual tumor volume and 
survival,and good responses to platinum-
based chemotherapy during the initial 
period.5 We present a case that was 
postoperatively diagnosed as primary 
tubal carcinoma in our clinic and discuss 
this case in comparison with others 





A 57-year-old woman presented at the 
Taksim Education and Research Hospital, 
Gynecology and Obstetrics Department 
on 12/24/2002, with prolapsed uterus and 
pollakiuria. Her complaint started 5-6 
months prior to presentation. She has 
been in menopause for six years with a 
previous history as follows: pregnancy 2, 
parity 2, abortus 0, curettage 0. She had 
a history of pelvic inflammatory disease 
and compensated diabetes mellitus (Type 
II). Vaginal examination showed 2 degree 
prolapse both on anterior-posterior wall of 
vagina with effort. There was an atrophic 
column with invisible fornices. The 9-10 
week-size uterus was anteverted.  A 
myoma 5-6 cm in diameter was detected 
in the posterior wall. Both adnexal regions 
were sensitive. Transvaginal 
ultrasonography (TVUSG) showed larger 
uterus sizes, anteversion and anteflexion 
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of the uterus, and an intramural-
subserous myoma in the posterior wall 
with a 52x53 mm diameter. Left ovary 
was normal in size. The right adnexal 
region contained areas of  hypo- and 
hyperechogen 4x5 cm in diameter. 
Cervicovaginal smear obtained one week 
before the operation was reported as 
inflammatory smear. The patient was 
preoperatively diagnosed with a tubo-
ovarian abscess with abdominal pain, 
tenderness and an eleveated fever with 
leukocytes and underwent urgent 
laparotomy. In exploration, a myoma in 
the posterior wall of the uterus 5-6 cm in 
diameter was discovered. Both ovaries 
were normal. Right tube showed 
hydrosalpinx 5-6 cm in diameter. There 
was little fluid in abdomen; fluid was 
assessed as reactive and aspirated for 
postoperative pathologic observation. 
Total abdominal hysterectomy+bilateral 
salpingo-oophorectomy (TAH+BSO) 
+colporrhaphy anterior+ colporrhaphy 
posterior was performed. She received a 
blood transfusion (1 unit) postoperatively 
and no complications during follow-up. 
Her sutures were removed and she was 
discharged on the sixth day. After 
pathologic diagnosis, CA- 125 was 375.5 
U/ml. The oncology department continued 
follow-up and planned systemic 
chemotheraphy with five rounds of 
cisplatin 60mg/m2 and cyclophosphamide 
600mg/m2. The patient did not tolerate 
chemotheraphy and only four rounds 
were adminstered. In accordance with the 
opinion of the Council of Oncology, the 
patient underwent complete irradiation 
with cobalt or photon energies of 23 MV 
(administering a daily dose of 2 Gy 
resulted in a total of 45–52 Gy in the 
pelvic areas) for  palliative purpose.  After 
these treatments, CA- 125 decreased to 
14 U/ml. The patient presented in the 
oncology clinic on 9/21/2004 with 
abdominal pain, abdominal distension 
and difficulty with defecation. A 10x12 cm 
pelvic mass and diffuse ascites were 
apparent by computerized tomography 
(CT) and ultrasonography (USG). The 
CA-125 was 111.7 U/ml. Paracentesis 
was performed and the patient denied 
survical intervention, therefore preventing 
restaging. She received radiotheraphy 
and, after one month, six rounds of 
systemic chemotheraphy with taxol and 
carboplatin was administered. On 
9/2/2005, she was scanned by magnetic 
resonance imaging because of increased 
tumor  markers and irregular vaginal cuff. 
Multiple lymphadenopathies, the largest 
of which was 3x2 cm in size, were viewed 
in both inguinal regions. There was 
diffuse edema in the inguinal region. 
Thorax  CT showed a few pretracheal 
lymph nodes 5 mm in diameter. Nodules 
approximately 5 mm in diameter were 
detected in the left lung superior lobe 
anterior side and in the inferior lobe 
superior segment. The case was 
assessed as stage 4. Chemotheraphy 





According to previously published reports, 
the average age for primary tubal 
carcinoma is between 55-60 years of age. 
Low parity number, late menopause time, 
chronic salpingitis, and infertility are 
frequently associated with carcinoma.6 
Our case was multipara and she did not 
have a history of late menopause time. 
Her most important risk factor was the 
history of pelvic inflammatory disease. In 
their study of 11 cases, Benjamin et al. 
estimated the average parity as 2.5 and 
reported that there is a lower association  
between tubal carcinoma and parity in 
comparison to the association with 
endometrial and ovarian carcinoma. In 
addition, they reported hypertension, 
diabetes mellitus and cerebrovascular 
events in their group. These diseases are 
frequent in aged populations, leading the 
authors to suggest that these diseases 
are not risk factors themselves but rather 
an age-associated factor.7 Our case had 
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compensated DM-2. The most frequent 
symptoms of tubal carcinoma are 
abdominal pain, vaginal discharge and 
bleeding. The pain is colic, and it can be 
continuous or knife-like. The reason for 
colic pain is increased peristaltism and 
lumen distension, which causes the pain 
to be continuous and disguising the 
origins.8 Latzko named the triad as “tubae 
profluence” that is formed with large 
watery vaginal discharge, colic pain in 
lower abdomen and adnexal mass. These 
characteristics are pathognomonic for 
tubal carcinoma. Today, this triad occurs 
in 3-14% of cases, a low ratio.9 Our case 
had inguinal pain in the absence of 
vaginal bleeding and discharge. In the 
literature, there are some cases that, 
while investigating for the etiology of 
ascites, tubal carcinoma was detected.10 
In advanced cases ascites can be found. 
Our case did not have ascites in the 
preoperative period. It is very difficult to 
diagnose a tubal carcinoma 
preoperatively. Our patient with a 
preoperative diagnosis of a tubo-ovarian 
abscess with abdominal pain, tenderness 
and an eleveated fever with leukocytes 
underwent urgent laparotomy. McGoldrich  
has reported that only one of 376 cases 
was diagnosed in preoperative period.11 
Eddy has reported 2 of 74 patients and 
Podratz has reported 3 of 47 patients 
were diagnosed preoperatively in their 
studies.12,13 In Turkey, Ayhan and et al. 
have reported that no diagnoses were 
made preoperatively in their study of eight 
cases.14 Two cases, which were operated 
because of Saundra Meigs syndrome and 
acute hemoperitoneum, were diagnosed 
with frozen sections.15 Atypic masses 
which are suspected and originated from 
the fallopian tube can be frozen and this 
can help with diagnosis. Our case was 
not diagnosed preoperatively. Tubal 
adenocarcinoma on the right side was 
assessed preoperatively as a tubaovarian 
abscess, and during the operation as  
hydrosalpinx. In addition, there was an 
inflammatory and purulent reaction in the 
tube that was adherent to the posterior 
uterus, with no abnormalities in the 
digestive tract identified. Analysis of 
frozen sections was not performed 
because this diagnosis was not 
considered. Due to its rarity, preoperative 
diagnosis of primary fallopian tube 
carcinoma is rarely made. It is usually 
misdiagnosed as ovarian carcinoma, 
tubo-ovarian abscess or ectopic 
pregnancy. Primary tubal carcinoma can 
appear as acute pelvic peritonitis.16 
Transvaginal ultrasonography provides 
important information to assess fallopian 
tube wall structure, luminal substance 
and the relations with pelvic structures. 
Kurjak et al. initially diagnosed stage 1 
tubal carcinoma using colored and pulsed 
doppler USG .17 A 60 year old woman 
was assessed with doppler USG; in 
papillary projections and solid areas of 
the mass resistance index (RI) was 0.39 
and pulsative index (PI) was 0.45. 
According to Doppler criteria, tubal 
carcinoma was the suspected diagnosis 
and pathology confirmed this diagnosis.18 
Podobnik et al. described a 69 year old 
patient with right low quadrant pain and 
excessive watery vaginal discharge. They 
performed USG and identified a 6x2x2.5 
cm complex mass next to the right ovary 
with an RI:0.34 and PI:0.62. 
Vascularization of other ovary was 
normal. During USG, diameter and 
substance of the mass changed and 
passage of the fluid to cavitas uteri was 
viewed. On the strength of these findings, 
diagnosis of tubal carcinoma was 
considered and histological diagnosis 
was reported as clear cell carcinoma of 
tuba.19 Kurjak, et al. diagnosed eight tubal 
carcinomas preoperatively. All of these 
different types of carcinomas showed low 
vascular flow and complex masses were 
defined. RI was between 0.29 and 0.40. 
They suggested in their articles that 
transvaginal colored Doppler was more 
reliable than other expensive methods.17 
We did not perform Doppler on our case, 
but Doppler USG assessment of clinically 
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complex masses can make contributions 
for a suspected diagnosis. CA 125 levels 
can also help in diagnosis, with increased 
levels in advanced stage cases. Authors 
are unanimous that it is more beneficial 
for follow up of remission and 
recurrence.20,21 In our case CA 125 
levels, which decreased after 
chemotheraphy, increased when 
recurrence occured. Also, decreased CA 
125 levels after chemotheraphy showed 
that response for treatment was 
successful. Diagnosis is usually with 
histopathologic observation. In 1950, Hu 
et al. suggested criteria to differantiate 
tubal and uterine carcinomas from other 
malignancies. This criteria was modified 
by Sedlis in 1978. Macroscopically the 
tube appears swollen. To diffentiate from 
hydrosalpinx and tuboovarian abscess is 
possible with uncovering of specimen. 
Lumen is generally full with papillary or 




Figure 1: Adenocarcinoma areas that contain small 
nucleoli, big, oval-circular, vesicular nuclei, some of 
them with bizarre nucleus, and columnar-cuboid cells 
with eosinophilic cytoplasm. 
 
In our case the tube showed a cystic 
appearance with a diamerter of 4 cm in its 
largest region. Cross-sectionly there was 
tumor proliferation in a papillary and solid 
style in lumen. Microscopic observation of 
this macroscopically-defined lesion 
showed tumor proliferation, some 
necrosis, solid development in papillaries 
and wall, small nucleolus, large, oval 
circular, vesicular nucleus, some of them 
with bizarre nucleus, and columnar-
cuboid cells with eosinophilic cytoplasm.  
 
 
Figure 2: Adenocarcinoma areas that contain small 
nucleoli, big, oval-circular, vesicular nuclei, some of 
them with bizarre nucleus, and columnar-cuboid cells 
with eosinophilic cytoplasm. 
There were tumor invasions into the 
cervix, myometrium, in both ovaries and 
in the opposite tube inside the lymphatics. 
There were malignant epithelial tumor 
cells in the abdominal elution fluid. The 
case was diagnosed as middle degree 
differentiated serous papillary 
adenocarcinoma. According to FIGO 
classification system, our case was 
assessed as in stage II c because there 
were ovary and/or uterus invasions and 
tumor cells in ascites and peritoneal 
washings.  
 
 Figure 3: Adenocarcinoma areas that contain small 
nucleoli, big, oval-circular, vesicular nuclei, some of 
them with bizarre nucleus, and columnar-cuboid cells 
with eosinophilic cytoplasm. 
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The use of pap smear for diagnosis of 
primary tubal carcinoma is controversial. 
There are different results for pap smears 
in the literature, some of them are 
associated with a very optimistic, with a 
>%25, positive result.24 If psammoma 
bodies are viewed in the cervicovaginal 
smear and the age of the patient is 
suitable, the possibility of tubal carcinoma 
should be considered.25  The treatment 
approach for primary tubal carcinoma is 
similar to the approach for ovary 
carcinoma. Basic treatment is bilateral 
salpingo-oophorectomy and abdominal 
hysterectomy. However, if staging is 
desired, the following should be 
performed during surgery: peritoneal 
washings, ascites sampling if present, 
biopsies from surface of diaphagm, 
infracolic omentectomy, and 
retroperitoneal lymph node sampling.26 
Cytoreductive surgery in stage 3 and 
stage 4 patients provides significiant 
contribution for prognosis.27 
Postoperative chemotheraphy is currently 
intravenous taxol and cisplatin 
combination as it is used with ovary 
carcinomas.28  In a phase II study of 24 
patients with advanced stage tubal 
adenocarcinoma (Stage 3:14, Stage 
4:10), patients received 
cyclophosphamide, adriamycin, cisplatin 
combination; 10 patients demonstrated a 
complete response and 6 patients a 
partial response (response ratio:95%, 
confidence interval (45%-84%)). 
Response ratios are assessed as 
moderate, and adverse effects are 
acceptable.29 TAH+BSO was performed. 
The patient had a partial response to 
postoperative chemotheraphy and 
second line chemotheraphy was 
performed for subsequent recurrence. 
Despite the size of the mass becoming 
smaller, it was not a satisfactory 
response. Postoperative radiotherapy is 
not recommended because efficiency is 
low and serious complications are 
common.30 We used radiotheraphy for 
palliative purposes in our case and there 
were not any complications. Initially 
radiotherapy is performed frequently but 
this therapy cannot prevent spreading to 
the upper abdomen.31  In our case 
radiotherapy could not control the 
disease, so it spread to the upper 
abdomen. In cases with tubal carcinoma, 
5-year survival is between 30- 50%, 
regardless of stage.32 The most important 
factor that affects the survival is the stage 
of the disease at the time of diagnosis. 
Benedet and Miller have estimated 5-year 
survival in their metaanalyse which 
contains 6 studies with a total of 278 
patients: Stage 1: 62%, Stage 2: 36%, 
Stage 3: 17%, Stage 4: 0%.8 Rosen et al. 
have estimated 5-year survival in their 
retrospective analyses with 115 patients: 
Stage 3 and 4:13.6%; Stage 1 and 2: 
50.8%. It is reported that to leave >2 cm 
tumor tissue after debulking significantly 
worsens the prognosis.33 Our case died 





Carcinoma of the fallopian tube should be 
considered in the differential diagnosis of 
the tubo-ovarian abscess in those who 
present with abdominal pain, pelvic 
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